Francesco Amati, Gloria Leonardi, Martina Contarini, Letizia Corinna Morlacchi, Anna Stainer, Giovanna Pizzamiglio, Stefano Aliberti, Francesco Blasi, Andrea Gramegna
{"title":"免疫缺陷和 CFTR 功能障碍:对患有囊性纤维化和 CFTR 相关疾病的成人进行系统筛查的结果。","authors":"Francesco Amati, Gloria Leonardi, Martina Contarini, Letizia Corinna Morlacchi, Anna Stainer, Giovanna Pizzamiglio, Stefano Aliberti, Francesco Blasi, Andrea Gramegna","doi":"10.1177/17534666241253945","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immunodeficiencies (IDs) are conditions caused by immune system dysfunctions which predispose to chronic infections. Cystic fibrosis (CF) patients are characterized by the presence of bronchiectasis filled with hyper-viscous secretions that constitute the ideal environment for infections. Although CF and IDs might share similarities in the pathophysiological mechanism of bronchiectasis development, they each offer different treatment options. We hypothesize that the introduction of a bundle of tests would increase the number of ID diagnoses among adults with Cystic Fibrosis Transmembrane conductance Regulator (CFTR) dysfunction.</p><p><strong>Objectives: </strong>The primary objectives of this study were (1) assessing the prevalence of IDs in CF and (2) defining clinical characteristics of adults with both CF and IDs. The secondary objectives were: (1) assessing the prevalence of IDs in CFTR-Related Disorder (CFTR-RD) patients; (2) comparing the prevalence of IDs in CF and CFTR-RD; (3) comparing the prevalence of treatable IDs in CF and CFTR-RD.</p><p><strong>Design: </strong>We conducted an observational, prospective, consecutive study on a cohort of 190 adult patients affected by CF or CFTR-RD.</p><p><strong>Methods: </strong>Blood samples underwent a standardized immunological screening, including complete white blood count, IgG, IgA, IgM, IgG subclasses, total IgE, lymphocyte subsets, and HIV test. Comprehensive clinical history was assessed to identify risk factors for secondary IDs.</p><p><strong>Results: </strong>We identify a high prevalence of immunodeficiencies among the entire cohort: 34 (20.1%) CF patients and 10 (47.6%) CFTR-RD patients are diagnosed with IDs <i>via</i> a blood screening. No statistically significant difference in terms of clinical characteristics was found between immunocompromised and immunocompetent CF patients.</p><p><strong>Conclusion: </strong>We identify a high prevalence of immunodeficiencies in both CF and CFTR-RD.</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666241253945"},"PeriodicalIF":3.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11189011/pdf/","citationCount":"0","resultStr":"{\"title\":\"Immunodeficiencies and CFTR dysfunction: results from a systematic screening in a cohort of adults with cystic fibrosis and CFTR-related disorders.\",\"authors\":\"Francesco Amati, Gloria Leonardi, Martina Contarini, Letizia Corinna Morlacchi, Anna Stainer, Giovanna Pizzamiglio, Stefano Aliberti, Francesco Blasi, Andrea Gramegna\",\"doi\":\"10.1177/17534666241253945\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Immunodeficiencies (IDs) are conditions caused by immune system dysfunctions which predispose to chronic infections. Cystic fibrosis (CF) patients are characterized by the presence of bronchiectasis filled with hyper-viscous secretions that constitute the ideal environment for infections. Although CF and IDs might share similarities in the pathophysiological mechanism of bronchiectasis development, they each offer different treatment options. We hypothesize that the introduction of a bundle of tests would increase the number of ID diagnoses among adults with Cystic Fibrosis Transmembrane conductance Regulator (CFTR) dysfunction.</p><p><strong>Objectives: </strong>The primary objectives of this study were (1) assessing the prevalence of IDs in CF and (2) defining clinical characteristics of adults with both CF and IDs. The secondary objectives were: (1) assessing the prevalence of IDs in CFTR-Related Disorder (CFTR-RD) patients; (2) comparing the prevalence of IDs in CF and CFTR-RD; (3) comparing the prevalence of treatable IDs in CF and CFTR-RD.</p><p><strong>Design: </strong>We conducted an observational, prospective, consecutive study on a cohort of 190 adult patients affected by CF or CFTR-RD.</p><p><strong>Methods: </strong>Blood samples underwent a standardized immunological screening, including complete white blood count, IgG, IgA, IgM, IgG subclasses, total IgE, lymphocyte subsets, and HIV test. Comprehensive clinical history was assessed to identify risk factors for secondary IDs.</p><p><strong>Results: </strong>We identify a high prevalence of immunodeficiencies among the entire cohort: 34 (20.1%) CF patients and 10 (47.6%) CFTR-RD patients are diagnosed with IDs <i>via</i> a blood screening. No statistically significant difference in terms of clinical characteristics was found between immunocompromised and immunocompetent CF patients.</p><p><strong>Conclusion: </strong>We identify a high prevalence of immunodeficiencies in both CF and CFTR-RD.</p>\",\"PeriodicalId\":22884,\"journal\":{\"name\":\"Therapeutic Advances in Respiratory Disease\",\"volume\":\"18 \",\"pages\":\"17534666241253945\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11189011/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Respiratory Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17534666241253945\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Respiratory Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17534666241253945","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
摘要
背景:免疫缺陷症(IDs)是由免疫系统功能障碍引起的疾病,容易导致慢性感染。囊性纤维化(CF)患者的特点是支气管扩张,支气管内充满高粘度分泌物,是感染的理想环境。虽然 CF 和 ID 在支气管扩张的病理生理机制上可能有相似之处,但它们提供的治疗方案却各不相同。我们假设,在囊性纤维化跨膜传导调节器(CFTR)功能失调的成人中,采用捆绑式检验将增加ID的诊断数量:本研究的首要目标是:(1) 评估 CF 中 ID 的患病率;(2) 确定同时患有 CF 和 ID 的成人的临床特征。次要目标是(1)评估ID在CFTR相关障碍(CFTR-RD)患者中的患病率;(2)比较ID在CF和CFTR-RD患者中的患病率;(3)比较可治疗的ID在CF和CFTR-RD患者中的患病率:我们对 190 名受 CF 或 CFTR-RD 影响的成年患者进行了一项观察性、前瞻性、连续性研究:血样接受标准化免疫学筛查,包括全血细胞白细胞计数、IgG、IgA、IgM、IgG 亚类、总 IgE、淋巴细胞亚群和 HIV 检测。对临床病史进行了全面评估,以确定继发性 ID 的风险因素:结果:我们发现整个队列中免疫缺陷的发病率很高:通过血液筛查,34 名 CF 患者(20.1%)和 10 名 CFTR-RD 患者(47.6%)被确诊为 IDs。免疫功能低下的 CF 患者和免疫功能正常的 CF 患者在临床特征方面没有明显的统计学差异:我们发现在 CF 和 CFTR-RD 患者中免疫缺陷的发病率都很高。
Immunodeficiencies and CFTR dysfunction: results from a systematic screening in a cohort of adults with cystic fibrosis and CFTR-related disorders.
Background: Immunodeficiencies (IDs) are conditions caused by immune system dysfunctions which predispose to chronic infections. Cystic fibrosis (CF) patients are characterized by the presence of bronchiectasis filled with hyper-viscous secretions that constitute the ideal environment for infections. Although CF and IDs might share similarities in the pathophysiological mechanism of bronchiectasis development, they each offer different treatment options. We hypothesize that the introduction of a bundle of tests would increase the number of ID diagnoses among adults with Cystic Fibrosis Transmembrane conductance Regulator (CFTR) dysfunction.
Objectives: The primary objectives of this study were (1) assessing the prevalence of IDs in CF and (2) defining clinical characteristics of adults with both CF and IDs. The secondary objectives were: (1) assessing the prevalence of IDs in CFTR-Related Disorder (CFTR-RD) patients; (2) comparing the prevalence of IDs in CF and CFTR-RD; (3) comparing the prevalence of treatable IDs in CF and CFTR-RD.
Design: We conducted an observational, prospective, consecutive study on a cohort of 190 adult patients affected by CF or CFTR-RD.
Methods: Blood samples underwent a standardized immunological screening, including complete white blood count, IgG, IgA, IgM, IgG subclasses, total IgE, lymphocyte subsets, and HIV test. Comprehensive clinical history was assessed to identify risk factors for secondary IDs.
Results: We identify a high prevalence of immunodeficiencies among the entire cohort: 34 (20.1%) CF patients and 10 (47.6%) CFTR-RD patients are diagnosed with IDs via a blood screening. No statistically significant difference in terms of clinical characteristics was found between immunocompromised and immunocompetent CF patients.
Conclusion: We identify a high prevalence of immunodeficiencies in both CF and CFTR-RD.
期刊介绍:
Therapeutic Advances in Respiratory Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of respiratory disease.